Harold J. Burstein, MD, PhD, and Lisa A. Carey, MD, on Innovations in Triple-Negative Breast Cancer
2014 San Antonio Breast Cancer Symposium
Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute and Lisa Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, discuss:
- The TNT trial comparing docetaxel to carboplatin
- The CALGB trial on response rates after neoadjuvant chemo with or without carboplatin or bevacizumab
- Pembrolizumab in a phase Ib study
Clifford A. Hudis, MD, FACP
Clifford A. Hudis, MD, FACP, of Memorial Sloan Kettering Cancer Center, discusses findings from abstract P5-19-09, “Stage 1 results from MDV3100-11: A two-stage study of enzalutamide, an androgen receptor inhibitor, in advanced androgen receptor–positive triple-negative breast cancer,” presented by Tiffany A. Traina, MD.
Ismail Jatoi, MD, PhD, FACS, and Clifford A. Hudis, MD, FACS
Ismail Jatoi, MD, PhD, FACS, and Clifford A. Hudis, MD, FACS, discuss the role of ovarian suppression and hormonal therapy in premenopausal women.
Ismail Jatoi, MD, PhD, FACS, and Ann H. Partridge, MD, MPH
Ismail Jatoi, MD, PhD, FACS, of the University of Texas Health Science Center and Ann H. Partridge, MD, MPH, of the Dana-Farber Cancer Institute discuss the increasing movement away from breast conservation toward bilateral surgical procedures.
Prudence Francis, MD, and Hope Rugo, MD
Prudence Francis, MD, of Peter MacCallum Cancer Centre, and Hope Rugo, MD, of the University of California, San Francisco, discuss data from abstract S3-08, "Randomized comparison of adjuvant tamoxifen plus ovarian function suppression vs tamoxifen in premenopausal women with hormone receptor–positive early breast cancer: Analysis of the SOFT trial."
